Quantcast

Latest Factor VII Stories

2015-04-16 08:33:02

DEERFIELD, Ill., April 16, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc.

2015-04-16 08:32:31

Landmark Lightings and Community Activities Honor People Affected by the Disorder WESTON, Mass., April 16, 2015 /PRNewswire/ -- In recognition of World Hemophilia Day,

2015-03-30 08:32:07

rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding Disorders KING OF PRUSSIA,

2015-03-26 12:30:04

PLAINSBORO, N.J., March 26, 2015 /PRNewswire/ -- Novo Nordisk today announced the company will launch Novoeight(®) (Antihemophilic Factor [Recombinant]) in the United States for people living

2015-02-11 08:33:15

DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc.

2015-02-04 12:26:50

CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL Behring's Legacy of Improving Patient Well-Being

2015-02-01 23:00:46

Researchmoz added new research report on Recombinant Coagulation Factors Pipeline Analysis to 2015 to its huge collection. Albany, NY (PRWEB) February 01, 2015

2015-01-30 12:25:45

COPENHAGEN, Denmark and SEATTLE, Jan. 30, 2015 /PRNewswire/ -- Serendex Pharmaceuticals A/S (XOSL: SENDEX) and CMC Biologics, Inc. have today signed an exclusive agreement on Factor VIIa.

2015-01-27 23:00:21

Marketresearchreports.biz has announced the addition of a new research study on the global and China blood product industry titled China Blood Product Industry Report 2014-2017 to its offering.

2015-01-27 16:27:13

DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant


Word of the Day
shotta
  • An armed gangster.
The word 'shotta' is an alteration of 'shooter'.